Dizal Pharmaceuticals initiates trial for DZD8586 in relapsed B-cell Non-Hodgkin Lymphoma
Dizal Pharmaceuticals is conducting a study on DZD8586 for patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma.
Company
Pharmaceutical intelligence for Dizal Pharmaceuticals with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.